Mangoceuticals Inc Dossier
Qualitative Analysis
Business overview
Mangoceuticals, Inc. (NASDAQ: MGRX) is a telemedicine-focused men's wellness company specializing in the development, marketing, and sale of compounded and FDA-approved products. Operating primarily through its secure direct-to-consumer (DTC) digital platform, "MangoRx," the company offers customized formulations for erectile dysfunction (ED), hair loss, hormone replacement therapy, and weight management. Its flagship product line includes sublingual oral disintegrating tablets (RDTs) under the "Mango" brand, alongside other wellness offerings such as "Grow" for hair loss, "Mojo," "Slim," and "PRIME" (an oral testosterone replacement therapy). Mangoceuticals utilizes a vertically integrated telehealth model, connecting patients with licensed physicians and fulfilling prescriptions through partner compounding pharmacies, with plans to acquire its own compounding facility to fully control its supply chain.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Launched an all-inclusive injectable TRT treatment program priced at $99 per month, which includes doctor visits, medical consultations, lab work, and prescribed medication delivered via its secure telemedicine platform.
Expected impact: Expected to serve as the primary near-term growth driver for the company, leveraging a 54% reduction in customer acquisition costs to capture market share in the global TRT market.
Established a new subsidiary, Mango DAT, LLC, in partnership with Cube Group to launch an up to $100 million Solana-focused digital asset treasury strategy utilizing a 'MULTI-DAT' framework.
Expected impact: Aims to generate non-dilutive growth through staking yields (targeting 7-8% APY) and active management (targeting 8-20% APY) on Solana assets.
Launched integrated programs providing direct access to authentic branded GLP-1 weight-management medications, Zepbound (tirzepatide) from Eli Lilly and Wegovy (semaglutide) from Novo Nordisk, via LillyDirect and NovoCare pharmacy solutions.
Expected impact: Expands the company's addressable market into the multi-billion-dollar obesity and weight-management sector by offering a $99/month telehealth membership with cash-pay medication options starting at $499/month.
Developing and securing global intellectual property protection for MGX-0024, a patented antiviral animal feed and drinking water additive designed to prevent respiratory diseases in commercial poultry.
Expected impact: Extends patent protection to over 150 countries, building on successful field trials showing zero respiratory-related mortality in 29,000 birds and prophylactic benefits against H5N1.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquired all intellectual property, product formulations, know-how, distribution, supplier relationships, and select assets of Smokeless Technology Corp. to enter the high-growth oral stimulant pouch market.
Financial impact: Funded via the issuance of common stock and convertible preferred shares, impacting the capital structure while establishing a foundation for non-pharmaceutical and nutraceutical pouch product lines.
Strategic Partnerships
Cube Group, led by Solana core developers Bartosz Lipinski and Larry Wu, was appointed as the asset manager responsible for custody, execution, and yield optimization of Mangoceuticals' up to $100 million Solana-focused digital asset treasury.
Terms: Cube Group will manage the portfolio targeting staking yields of 7-8% APY and active management yields of 8-20% APY.
Collaborating on the development, testing, and global patent protection of the antiviral animal feed and drinking water additive technology powering MGX-0024.
Terms: Jointly filed a Patent Cooperation Treaty (PCT) application on February 26, 2026, to secure global rights.